Conflicts of interest always present problems (to some degree)

As our friend Howard Wolinsky continues his journalistic exploits into the world of prostate cancer, he has (almost inevitably) come across an issue of “conflicts of interest”, … READ MORE …

A chance for US patients to “speak to power”

The roles of patients, patient advocates, and other members of the public in decision-making about the research that is funded by NIH and other agencies here in America is sadly somewhat limited, … READ MORE …

Early data suggest 18F-DCFPyL PET/CT scans can change patient management

A media release issued yesterday by Progenics Pharmaceuticals states that the investigational imaging agent 18F-DCFPyL changed physician behavior in the management of biochemically recurrent prostate cancer in > 65 percent of patients. … READ MORE …

Depression in men on ADT

Depression is relatively common among men with prostate cancer. Indeed, it may be a lot more common than we can currently document. … READ MORE …

Long-term follow-up data from LATITUDE trial

Long-term follow-up data from the LATITUDE trial have now been published by Fizazi et al. in Lancet Oncology. … READ MORE …

Germline genetic testing for men with prostate cancer

In this week’s Journal of Clinical Oncology, there is a full-text article in the “Comments and Controversies” section entitled … READ MORE …

The use of the word “survivor” can arouse strong feelings

In his latest epistle on living with cancer on MedPage Today, Howard Wolinsky addresses what he has come to understand is a very sensitive topic. … READ MORE …